You've sold the same Class I device for 20 years with no serious incidents, a clean complaint file, and a product clinicians reach for without thinking twice. Then your notified body asks for post-market clinical follow-up data, and all they hear is crickets...
I hear versions of that story on the podcast constantly. The frustration is fair, and it usually rides in on one specific question: what am I supposed to follow up on when the device already works?
Post-Market Clinical Follow-up (PMCF) is part of staying compliant under the EU Medical Device Regulation (MDR), and it reaches more products than most teams expect. That includes Class I and IIa devices and well-established technologies (WETs). Sutures, wires, and dental braces all live in that category.
Here's the reassuring part for these devices. PMCF rarely has to look like a full interventional study. For a low-risk product with a long track record, surveys and structured clinical experience usually carry the evidence you need.
The EU MDR asks for "sufficient clinical evidence" and then, unhelpfully, never defines the phrase. MDCG 2020-6 provides that definition. It defines what qualifies as a well-established technology, and its evidence hierarchy leaves room for lower-tier data when a device is mature and its risks are understood. MDCG 2020-6 is the reason a well-run survey program can hold up for a WET where a trial would be overkill.
Here's where teams get tripped up. A long, boring safety record feels like proof that follow-up is optional. A known safety profile doesn't account for new use patterns, new user populations, or the failure modes that only surface once a device is out in the world at volume. PMCF exists to catch those early, while they're still cheap to fix.
Think of a PMCF plan as the recipe, not the meal. It sets the methods, the questions, and the cadence for gathering data you'll actually use, both for reporting and for making the product better. PMCF is a standing process, not a box you tick once and forget.
What a well-built PMCF program buys you
Get this right and the program earns its keep in three ways.
Catching emerging risks early
Manufacturers and clinical teams spot the first signs of trouble sooner, whether that's user dissatisfaction or a technical failure nobody modeled. Earlier signal means earlier fixes, and earlier fixes are cheaper ones.
Backing performance claims with real data
Every claim in your clinical evaluation report needs evidence under it. PMCF gives you quantified, analyzed data on how the device performs and how safe it is once real clinicians use it at volume.
Feeding real-world learning back into the device
The data points to concrete improvements, from clearer labeling to design changes that make the next version measurably better.
PMCF methods, and which ones fit low-risk devices
PMCF activities fall into three broad categories: surveys, clinical experience, and interventional clinical investigations. Cost and timeline climb steeply from the first to the last.
For lower-class devices and WETs, I'd reach for surveys and clinical experience almost every time. A full investigation is expensive, slow, and often unnecessary to answer the questions a mature device actually raises. There are real alternatives to a full-scale investigation, and for most low-risk devices they're the smarter opening move.
Clinical experience is where a lot of the best data hides. Clinicians who use the device every day can report on performance and safety through existing medical records, without the wait for regulatory clearance that a formal study demands. Published clinical experience often stands on its own as a credible source.
Surveys deserve a word of caution, though. A sloppy questionnaire produces data a notified body will wave off. If you go that route, build it like a study, with defined endpoints, a justified sample size, and a validated collection tool. Our guide on running a PMCF survey that holds up walks through the details.
Where PMCF programs actually break down
Most PMCF struggles aren't scientific. They're organizational. Clinical teams that treat data collection as a side task, without the right tools or a shared plan, end up with gaps that surface at the worst possible time.
The organizational side
Plenty of clinics lack the structure and the data habit to run routine PMCF, and readiness matters as much as good intentions. The tools, the methods, and the standard operating procedures all have to exist before the first data point lands.
The data and analysis side
Some teams don't have the infrastructure or the statistical footing to pull clean, usable data. Paper forms and Excel sheets are the usual culprits. They won't give you a single defensible database, and they don't meet ISO 14155:2020, which is the standard your survey data has to satisfy before you can use it in your clinical evaluation.
A purpose-built system changes the math entirely. One database, structured fields, and cross-functional access mean marketing, clinical, and quality are all reading from the same page. You get cleaner inputs, fewer dropped participants, and faster reporting out the other end.
Good documentation ties it together: a current clinical evaluation report (CER), up-to-date device status, and PMCF templates that make collection repeatable. Run the whole thing through your quality management system (QMS) before you start. Stale contact details or a mismatched record will burn time you don't have, without you even realizing it.
PMCF in practice: two use cases
Evnia and Greenlight Guru Clinical have worked through this with real manufacturers, and two examples show how different the same problem can look.
A WET device with 20 years of use and no PMCF habit
The client had a well-established device with more than two decades of clinical use, no history of planned data collection, and clinical evaluation reports too thin to drive real decisions. The answer was ad-hoc case-series reporting, where named clinical experts contribute data directly, rather than the anonymous responses most surveys collect. The forms read like plain questionnaires but pulled data across a whole device family, with full control over endpoint design. The team cross-checked claims against the software requirements, the instructions for use, and marketing, then aimed collection at the quantitative data that actually backs performance and safety.
A top-three hearing aid maker that needed the end-user voice
The hearing aid maker needed input straight from end users and had little appetite for a study-based approach. Access ran through distributors, so the clinical team started there: identify the distributors, sign the agreements, and prove the value before asking anyone for a single data point. Timing mattered as much as the questions, so the team mapped the user workflow to find the right moment to ask.
The tool was an ePRO (electronic patient-reported outcomes) setup, built as a questionnaire behind a clean public enrollment page. Recruiting happened locally while data came in globally. The result was almost 200 cases across more than 10 countries, from North America to Europe to Southeast Asia, collected in roughly three months.
Where this leaves you
If you make a low-risk device or a WET, here's what actually matters: PMCF can be proportionate. Match the method to the risk, run it on a system that meets ISO 14155:2020, and treat the data as a live feed into your CER and your risk file rather than a once-a-year scramble.
The regulatory ground keeps shifting under all of this. MDCG 2020-6 and 2020-7 still set the expectations, the MDR transition timelines have moved more than once, and the European Commission floated a targeted MDR revision in late 2025 that's still working its way through Brussels. But that doesn't change the core move for a mature device. Gather proportionate clinical experience, keep it clean, and keep it current.
Keep reading
If you are building out your PMCF process, these related guides go deeper on the specific components:
- Post-Market Clinical Follow-up under EU MDR: guide to PMCF activities
- How to design a successful PMCF survey
- MDCG 2020-6 explained: sufficient clinical evidence for legacy devices
- PMCF data collection: when surveys work, when they don't, and what regulators expect
- What EU MDR clinical evaluation requires
- Alternatives to PMCF clinical investigations
Help with PMCF data collection and management
Greenlight Guru Clinical is the electronic data capture (EDC) software built for the regulatory reality and clinical workflow of medtech, not adapted from a pharma tool. For PMCF under EU MDR, it handles survey and case-series collection, comes pre-validated to ISO 14155:2020 and 21 CFR Part 11, and keeps your data in one place instead of scattered across spreadsheets. See how Greenlight Guru Clinical can simplify your PMCF data collection and compliance.
GET A DEMO: Click here to see Greenlight Guru Clinical in action.
P.S. That 20-year-old device you were sure had nothing left to teach you? Its clinicians are the best PMCF instrument you own. Give them an easy way to communicate with you, and they'll tell you things your complaint file never will.
BONUS RESOURCE: Change Impact Analysis Checklist
